通心络胶囊用于急性心肌梗死后二级预防的系统评价与Meta分析
该系统评价纳入19项随机对照试验(RCT),其中16项进行Meta分析,评估通心络胶囊(TXL)对急性心肌梗死(AMI)后二级预防的潜在有效性与安全性。结果显示TXL可降低主要心血管事件(心脏死亡、再梗死、心律失常、再发心绞痛),改善左室射血分数(LVEF)并调节血脂和hs-CRP,但对血运重建、再发心衰和HDL-C影响不显著,且胃肠道不适更常见。结论认为TXL可能有益,但需更严谨的RCT进一步验证。
要点
- TXL可降低AMI后心脏死亡、再梗死、心律失常和再发心绞痛风险。
- TXL改善LVEF并降低TC、TG、LDL-C及hs-CRP,对HDL-C无显著影响。
- TXL对血运重建和再发心衰无显著效果,且胃肠道不适更常见。
核心结论
- 通心络胶囊对急性心肌梗死后二级预防可能有益,但需更严谨的RCT进一步评估。
主要发现
- TXL组降低心脏死亡(RR=0.27,95%CI:0.08~0.95,I²=0%)、再发心肌梗死(RR=0.38,95%CI:0.20~0.74,I²=0%)、心律失常(RR=0.44,95%CI:0.30~0.66,I²=0%)和再发心绞痛(RR=0.34,95%CI:0.17~0.69,I²=0%)。
- TXL改善LVEF(MD=4.10,95%CI:3.95~4.25,I²=0%),降低TC(MD=-0.66,95%CI:-0.94~-0.37,I²=74%)、TG(MD=-0.38,95%CI:-0.62~-0.14,I²=70%)、LDL-C(MD=-0.40,95%CI:-0.65~-0.16,I²=88%)及hs-CRP(4周:MD=-0.78,95%CI:-0.97~-0.60,I²=20%;超过4周:MD=-1.36,95%CI:-1.55~-1.17,I²=20%)。
- TXL对血运重建(RR=0.45,95%CI:0.13~1.56,I²=0%)、再发心衰(RR=0.83,95%CI:0.27~2.57,I²=0%)和HDL-C(MD=0.14,95%CI:0.00~0.29,I²=73%)无显著影响。
- TXL组更易出现胃肠道不适。
关键数值与推荐
- 心脏死亡RR=0.27(95%CI:0.08~0.95,I²=0%),再发心肌梗死RR=0.38(95%CI:0.20~0.74,I²=0%)。
- 心律失常RR=0.44(95%CI:0.30~0.66,I²=0%),再发心绞痛RR=0.34(95%CI:0.17~0.69,I²=0%)。
- LVEF MD=4.10(95%CI:3.95~4.25,I²=0%),TC MD=-0.66(95%CI:-0.94~-0.37,I²=74%)。
- TG MD=-0.38(95%CI:-0.62~-0.14,I²=70%),LDL-C MD=-0.40(95%CI:-0.65~-0.16,I²=88%)。
- hs-CRP 4周MD=-0.78(95%CI:-0.97~-0.60,I²=20%),超过4周MD=-1.36(95%CI:-1.55~-1.17,I²=20%)。
临床怎么用
- 在AMI后二级预防中,可考虑在常规治疗基础上加用通心络胶囊以降低心血管事件风险并改善心功能及炎症指标。
- 使用通心络胶囊时需关注胃肠道不适,尤其对于有胃肠道疾病史的患者。
- 通心络胶囊对血运重建和再发心衰无显著益处,不应替代必要的血运重建治疗。
局限性
- 纳入的RCT方法学质量可能有限,证据质量需结合GRADE评价结果。
- 部分结局指标异质性较高(如TC、TG、LDL-C、HDL-C)。
- 需要更多严谨设计的RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Chinese patent medicine Tongxinluo capsule (TXL) is commonly used for cardio-cerebrovascular diseases. Previous research had demonstrated that TXL exhibited great clinical effects on the treatment of acute myocardial infarction (AMI), however there is a lack of systematic review. The purpose of this study was to evaluate the potential effectiveness and safety of TXL for secondary prevention in patients with AMI. Method: We searched 6 databases to identify relevant randomized controlled trials (RCTs) from inceptions to December 30, 2017. Two review authors independently assessed the methodological quality and analyzed data by the RevMan 5.3 software. The publication bias was assessed through funnel plot and Begg's test. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used for evaluating the quality of evidence. Results: We included 19 RCTs in this review and performed a meta-analysis based on 16 studies. There were statistical differences of TXL treatment group in reducing primary cardiovascular events (cardiac death [RR = 0.27, 95%CI: 0.08~0.95, I2 = 0%], recurrent myocardial reinfarction [RR = 0.38, 95%CI: 0.20~0.74, I2 = 0%], arrhythmia [RR = 0.44, 95%CI: 0.30~0.66, I2 = 0%], recurrent angina pectoris [RR = 0.34, 95%CI: 0.17~0.69, I2 = 0%]). TXL could improve cardiac function (LVEF [MD = 4.10, 95%CI: 3.95~4.25, I2 = 0%]), regulate blood lipid TC [MD = -0.66, 95%CI: -0.94 ~ -0.37, I2 = 74%], TG [MD = -0.38, 95%CI: -0.62 ~ -0.14, I2 = 70%], LDL-C[-0.40, 95%CI: -0.65 ~ -0.16, I2 = 88%), decrease the level of hs-CRP (4-week: MD = -0.78, 95%CI: -0.97 ~ -0.60, I2 = 20%; Over 4-week: MD = -1.36, 95%CI: -1.55 ~ -1.17, I2 = 20%). However, TXL has little effects on revascularization [RR = 0.45, 95%CI: 0.13~1.56, I2 = 0%], recurrent heart failure (RR = 0.83, 95%CI: 0.27~2.57, I2 = 0%), and HDL-C (MD = 0.14, 95%CI: 0.00 ~0.29, I2 = 73%). Furthermore, TXL treatment group was more prone to suffer gastrointestinal discomfort. Conclusion: Chinese patent medicine TXL seemed beneficial for secondary prevention after AMI. This potential benefit needs to be further assessed through more rigorous RCTs. Systematic review registration number in the PROSPERO register: CRD42017068417.
引用
- Li M, Li C, Chen S, et al. Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2018. PMID: 30123126. doi:10.3389/fphar.2018.00830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。